跳转至内容
Merck
CN
  • Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals.

Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals.

Journal of aerosol medicine and pulmonary drug delivery (2015-10-16)
David Cipolla, Huiying Wu, Igor Gonda, Hak-Kim Chan
摘要

Previously we showed that the release properties of a liposomal ciprofloxacin (CFI) formulation could be attenuated by incorporation of drug nanocrystals within the vesicles. Rather than forming these drug nanocrystals during drug loading, they were created post manufacture simply by freezing and thawing the formulation. The addition of surfactant to CFI, either polysorbate 20 or Brij 30, provided an additional means to modify the release profile or incorporate an immediate-release or 'burst' component as well. The goal of this study was to develop a CFI formulation that retained its nanocrystalline morphology and attenuated release profile after delivery as an inhaled aerosol. Preparations of 12.5 mg/mL CFI containing 90 mg/mL sucrose and 0.1% polysorbate 20 were formulated between pH 4.6 to 5.9, stored frozen, and thawed prior to use. These thawed formulations, before and after mesh nebulization, and after subsequent refrigerated storage for up to 6 weeks, were characterized in terms of liposome structure by cryogenic transmission electron microscopy (cryo-TEM) imaging, vesicle size by dynamic light scattering, pH, drug encapsulation by centrifugation-filtration, and in vitro release (IVR) performance. Within the narrower pH range of 4.9 to 5.3, these 12.5 mg/mL liposomal ciprofloxacin formulations containing 90 mg/mL sucrose and 0.1% polysorbate 20 retained their physicochemical stability for an additional 3 months refrigerated storage post freeze-thaw, were robust to mesh nebulization maintaining their vesicular form containing nanocrystalline drug and an associated slower release profile, and formed respirable aerosols with a mass median aerodynamic diameter (MMAD) of ∼3.9 μm and a geometric standard deviation (GSD) of ∼1.5. This study demonstrates that an attenuated release liposomal ciprofloxacin formulation can be created through incorporation of drug nanocrystals in response to freeze-thaw, and the formulation retains its physicochemical properties after aerosolization by mesh nebulizer.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
三乙基胺, ≥99.5%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
氯化钠, Molecular Biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
氯化钠 溶液, 5 M in H2O, BioReagent, Molecular Biology, suitable for cell culture
Sigma-Aldrich
氯化钠, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
氯化钠, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
氯化钠 溶液, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
三乙基胺, ≥99%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
三乙基胺, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
三乙基胺, puriss. p.a., ≥99.5% (GC)
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
氯化钠 溶液, 5 M
Sigma-Aldrich
蔗糖, ACS reagent
Sigma-Aldrich
HEPES缓冲溶液, 1 M in H2O
Sigma-Aldrich
甲醇, BioReagent, ≥99.93%
Sigma-Aldrich
氯化钠, BioUltra, Molecular Biology, ≥99.5% (AT)
Sigma-Aldrich
HEPES, BioUltra, Molecular Biology, ≥99.5% (T)
Sigma-Aldrich
氯化钠, meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%
Sigma-Aldrich
氯化钠 溶液, BioUltra, Molecular Biology, ~5 M in H2O
Sigma-Aldrich
氯化钠, 99.999% trace metals basis
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
蔗糖, puriss., meets analytical specification of Ph. Eur., BP, NF
Sigma-Aldrich
三乙基胺, for amino acid analysis, ≥99.5% (GC)
Sigma-Aldrich
HEPES, BioXtra, suitable for mouse embryo cell culture, ≥99.5% (titration)